BGI, China
12
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
Role: lead
A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis
Role: collaborator
Spatially Resolved IBD: Spatial Transcriptomics of Inflammatory Bowel Disease (IBD)
Role: collaborator
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Role: lead
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.
Role: collaborator
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Role: lead
HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors
Role: lead
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
Role: lead
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
Role: lead
Probiotics as Adjuvant Treatment for Bacterial Vaginosis
Role: collaborator
Colon Cancer Study of Fecal Samples in Shanghai, China
Role: collaborator
TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor
Role: lead
All 12 trials loaded